Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Parenteral nutrition for adult and pediatric patients when oral or enteral nutrition is not possible or insufficient,Metabolic stress states such as trauma, sepsis, or burns (off-label use)
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 m L/kg/hr initially, titrate up to 100-125 m L/hr. Do not exceed 125 m L/hr.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Amino acids: variable, ~1-2 hours for most, reflecting rapid metabolism and utilization. Dextrose: not applicable as endogenous molecule; infusion half-life ~15-30 minutes due to insulin-mediated clearance. Clinical context: renal impairment prolongs amino acid elimination.
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; electrolytes are excreted or reabsorbed by the kidneys.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
Amino acids and electrolytes are primarily excreted renally. Dextrose is metabolized to CO2 and water, exhaled via lungs. Unmetabolized dextrose excreted renally if threshold exceeded. Less than 5% biliary/fecal.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Amino acids: minimal (<10%), mainly to albumin. Dextrose: not bound. Electrolytes: variably bound (e.g., calcium ~40% to albumin).
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Amino acids: ~0.5-1 L/kg, reflecting distribution to total body water. Dextrose: ~0.2-0.3 L/kg (extracellular). Electrolytes: Vd varies (e.g., calcium ~0.5 L/kg).
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
Intravenous: 100%.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
GFR > 50 m L/min: no adjustment. GFR 30-50 m L/min: reduce amino acid dose to 0.5-1 g/kg/day. GFR 15-29 m L/min: 0.5-0.8 g/kg/day. GFR < 15 m L/min (not on dialysis): restrict to 0.4-0.6 g/kg/day. Monitor electrolytes closely.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
Child-Pugh A: usual dose. Child-Pugh B: reduce amino acid dose by 25-50% and monitor ammonia levels. Child-Pugh C: avoid or use with extreme caution; use specially formulated solutions (e.g., branched-chain amino acid enriched).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Intravenous infusion. Neonates: 1.5-3 g amino acids/kg/day, dextrose 4-8 mg/kg/min. Infants: 2-3 g amino acids/kg/day, dextrose 10-15 mg/kg/min. Children: 1.5-2 g amino acids/kg/day, dextrose 5-10 mg/kg/min. Rate adjusted per tolerance and fluid requirements.
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 1.0-1.5 g amino acids/kg/day and 5-10 g dextrose/kg/day). Monitor glucose, electrolytes, and renal function closely. Adjust rate to avoid fluid overload.
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
This product contains aluminum that may be toxic. Patients with impaired kidney function, including premature neonates, may accumulate aluminum at levels associated with CNS and bone toxicity.
None
Monitor serum glucose, electrolytes, and acid-base status; risk of hyperglycemia, electrolyte imbalances, and metabolic acidosis; use caution in renal or hepatic impairment; aluminum toxicity risk with prolonged use.
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
Hypersensitivity to any component, severe hyperglycemia, uncontrolled metabolic acidosis, severe electrolyte disturbances, and acute pulmonary edema or cardiac decompensation.
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
No oral food or enteral feedings while receiving this parenteral nutrition unless specifically prescribed. Avoid alcohol, which can worsen electrolyte imbalances or liver stress. Some components may interact with anticoagulants (e.g., vitamin K in amino acids) but no specific food restrictions.
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a parenteral nutrition solution. Dextrose and electrolytes are essential nutrients; no teratogenic risk is expected with appropriate use. However, calcium gluconate may cause fetal hypocalcemia if maternal levels are imbalanced. First trimester: no known teratogenicity. Second trimester: metabolic disturbances may occur if maternal homeostasis is disrupted. Third trimester: risk of neonatal hypoglycemia if maternal glucose levels are high; risk of fetal hypercalcemia or hypocalcemia if calcium levels are abnormal.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
Dextrose, amino acids, and electrolytes are endogenous and normally present in breast milk. Calcium is secreted into milk; maternal supplementation may increase milk calcium concentration. No specific M/P ratio is available. Use with caution; monitor infant for gastrointestinal effects. Compatible with breastfeeding when used as directed.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
Pregnancy increases plasma volume and renal blood flow, potentially altering electrolyte requirements and clearance. Dose adjustments may be needed for calcium and magnesium due to increased maternal demand and protein binding changes. Glucose metabolism is altered; monitor glucose tolerance and adjust dextrose infusion rate to avoid hyperglycemia. No specific dose adjustment guidelines exist; individualize based on clinical monitoring.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
CLINIMIX E 5/10 is a dual-chamber bag containing amino acids with electrolytes and dextrose. Do not use if the bag has been frozen or if the solution is discolored or contains particulates. Invert the bag to mix the contents thoroughly before administration. Do not administer simultaneously with blood through the same infusion set due to risk of pseudogglutination. Monitor serum glucose, electrolytes, and fluid balance closely, especially in patients with renal impairment, diabetes, or fluid overload. Use a dedicated line or a filter if required per protocol.
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
This medication is a sterile solution that provides nutrition and calories through a vein. It should only be administered by a healthcare professional.,Tell your doctor if you have kidney problems, diabetes, or fluid retention, as they may need to adjust the dosage.,Report any signs of infection at the IV site (redness, swelling, pain), fever, chills, or difficulty breathing.,Do not eat or drink anything unless instructed by your doctor, as this solution is meant to replace or supplement oral nutrition.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and kidney function.
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6), answered by our medical review team.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.. AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 m L/kg/hr initially, titrate up to 100-125 m L/hr. Do not exceed 125 m L/hr.. The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a parenteral nutrition solution. Dextrose and electrolytes are essential nutrients; no tera. AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.